Edition:
United Kingdom

Eagle Pharmaceuticals Inc (EGRX.OQ)

EGRX.OQ on NASDAQ Stock Exchange Global Market

65.84USD
23 May 2018
Change (% chg)

-- (--)
Prev Close
$65.84
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
93,583
52-wk High
$84.20
52-wk Low
$45.05

Latest Key Developments (Source: Significant Developments)

Eagle Pharmaceuticals Reports Q4 EPS Of $0.58
Monday, 26 Feb 2018 

Feb 26 (Reuters) - Eagle Pharmaceuticals Inc ::EAGLE PHARMACEUTICALS, INC. REPORTS FOURTH QUARTER AND FULL YEAR 2017 RESULTS.Q4 ADJUSTED NON-GAAP EARNINGS PER SHARE $1.00.Q4 EARNINGS PER SHARE $0.58.Q4 REVENUE $46.8 MILLION VERSUS $81.1 MILLION.Q4 EARNINGS PER SHARE VIEW $1.00, REVENUE VIEW $52.9 MILLION -- THOMSON REUTERS I/B/E/S.2018 RESEARCH AND DEVELOPMENT EXPENSE IS EXPECTED TO BE IN RANGE OF $46 MILLION TO $50 MILLION.  Full Article

Iridian Asset Management Reports 10.1 Pct Passive Stake In Eagle Pharmaceuticals
Monday, 8 Jan 2018 

Jan 8 (Reuters) - Iridian Asset Management::IRIDIAN ASSET MANAGEMENT REPORTS 10.1 PERCENT PASSIVE STAKE IN EAGLE PHARMACEUTICALS AS OF DEC 31, 2017 - SEC FILING‍​.  Full Article

Eagle Pharmaceuticals Commences Pivotal Study For Fulvestrant
Thursday, 7 Dec 2017 

Dec 7 (Reuters) - Eagle Pharmaceuticals Inc ::EAGLE PHARMACEUTICALS COMMENCES PIVOTAL STUDY FOR FULVESTRANT.EAGLE PHARMACEUTICALS- ANTICIPATES COMPLETION OF FULVESTRANT STUDY WITHIN TWELVE MONTHS, AND AN EXPECTED NDA FILING IN Q4 OF 2018.  Full Article

Eagle Pharmaceuticals Q3 earnings per share $0.98
Wednesday, 8 Nov 2017 

Nov 8 (Reuters) - Eagle Pharmaceuticals Inc :Eagle Pharmaceuticals Inc reports third quarter 2017 results.Q3 adjusted non-GAAP earnings per share $1.22.Q3 earnings per share $0.98.Q3 revenue $63 million versus I/B/E/S view $51.9 million.Q3 earnings per share view $0.80 -- Thomson Reuters I/B/E/S.Expect full year 2017 research and development expense will be consistent with upper end of $31-$35 million range​.Plan to begin dosing patients in Fulvestrant study in a few weeks and expect to file an NDA in Q4 of 2018​.Expect full year 2017 SG&A expense to be in range of $67 million - $70 million, slightly higher than previous guidance​.Will continue purchasing up to an additional $100 million shares under current share repurchase plan​.On PEMFEXY, says "hope to find a way to market" as soon as possible, once co's litigation with Eli Lilly is resolved​.  Full Article

EAGLE PHARMACEUTICALS RECEIVES TENTATIVE FDA APPROVAL FOR PEMFEXY
Friday, 27 Oct 2017 

Oct 27 (Reuters) - Eagle Pharmaceuticals Inc ::EAGLE PHARMACEUTICALS RECEIVES TENTATIVE FDA APPROVAL FOR PEMFEXY (PEMETREXED INJECTION) READY-TO-DILUTE.EAGLE PHARMACEUTICALS INC - ‍FDA HAS GRANTED TENTATIVE APPROVAL FOR COMPANY'S PEMFEXY​.  Full Article

Eagle Pharmaceuticals licenses Japanese rights for Bendamustine HCl
Wednesday, 20 Sep 2017 

Sept 20 (Reuters) - Eagle Pharmaceuticals Inc :Eagle Pharmaceuticals licenses Japanese rights for Bendamustine Hydrochloride ready-to-dilute and rapid infusion injection products to Symbio Pharmaceuticals Limited.$12.5 million upfront payment plus future potential milestones and royalty payments are part of deal​.Symbio has estimated that sales of Treakisym are estimated to grow to $90 million in 2018​.Company will also receive royalties on future net sales of licensed Bendamustine products.Symbio will target for approval of a product in 2020​.  Full Article

EAGLE PHARMACEUTICALS ANNOUNCES POSITIVE RESULTS OF STUDY CONDUCTED TO EVALUATE NEUROPROTECTIVE EFFECTS OF RYANODEX SECONDARY TO NERVE AGENT EXPOSURE
Tuesday, 5 Sep 2017 

Sept 5 (Reuters) - Eagle Pharmaceuticals Inc :EAGLE PHARMACEUTICALS ANNOUNCES POSITIVE RESULTS OF STUDY CONDUCTED TO EVALUATE NEUROPROTECTIVE EFFECTS OF RYANODEX SECONDARY TO NERVE AGENT EXPOSURE.SAYS ‍ANALYSIS OF NEUROPATHOLOGY​ SHOWED LOWER LEVEL OF BRAIN CELL NECROSIS IN ANIMALS TREATED WITH RYANODEX + AEDS, COMPARED TO AEDS ALONE.SAYS ‍IN ADDITION, NO SAFETY ISSUES WERE OBSERVED IN ANIMALS TREATED WITH RYANODEX​.  Full Article

Park West Asset Management reports 5.2 percent passive stake in Eagle Pharmaceuticals as on Aug 14, 2017
Thursday, 24 Aug 2017 

Aug 24 (Reuters) - Eagle Pharmaceuticals Inc :Park West Asset Management LLC reports 5.2 percent passive stake in Eagle Pharmaceuticals Inc as on August 14, 2017 - SEC filing​.  Full Article

Eagle Pharmaceuticals posts Q2 adj. earnings $0.49/shr
Wednesday, 9 Aug 2017 

Aug 9 (Reuters) - Eagle Pharmaceuticals Inc :Eagle Pharmaceuticals Inc reports second quarter 2017 results.Q2 earnings per share $0.28.Q2 adjusted non-GAAP earnings per share $0.49.Q2 revenue $50.1 million versus I/B/E/S view $52.5 million.Q2 earnings per share view $0.51 -- Thomson Reuters I/B/E/S.Eagle Pharmaceuticals Inc - board of directors approved an additional share buyback program of $100 million.Eagle Pharmaceuticals Inc - ‍2017 SG&A and research and development guidance remains unchanged​.Eagle Pharmaceuticals Inc - ‍company enters into $150 million amended and restated credit agreement​.Eagle Pharmaceuticals Inc - ‍implements initial expense reduction program​.Eagle Pharmaceuticals Inc - ‍have identified $10 million in expense reductions on an annualized basis which will begin impacting company's P&L in 2018​.  Full Article

Eagle Pharmaceuticals gets complete response letter from FDA on Ryanodex
Wednesday, 26 Jul 2017 

July 26 (Reuters) - Eagle Pharmaceuticals Inc ::Eagle pharmaceuticals receives complete response letter from FDA on Ryanodex for exertional heat stroke application.‍FDA has requested that company conduct an additional clinical trial for Ryanodex for exertional heat stroke​.Reviewing options and will evaluate FDA's response regarding Ryanodex​.  Full Article

BRIEF-Eagle Pharmaceuticals Gets Final FDA Approval For Bendamustine Hydrochloride Ready-To-Dilute Solution In 500Ml Admixture

* EAGLE PHARMACEUTICALS INC GRANTED FINAL FDA APPROVAL FOR BENDAMUSTINE HYDROCHLORIDE READY-TO-DILUTE SOLUTION IN A 500ML ADMIXTURE